New study monitors RSV vaccine safety in seniors
NCT ID NCT06546800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is checking the safety of the Abrysvo RSV vaccine in adults aged 60 and older in everyday medical practice in Japan. About 1100 people who get the vaccine will be watched for side effects for 28 days. The goal is to confirm the vaccine is safe for older adults.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple breath test catch flu in High-HIV regions?
- RSV drug trial for kids under 5 halted early – only 4 children enrolled
- Could a shot for moms shield babies from deadly RSV?
- RSV study seeks immune clues in older adults
- New study aims to predict severe bronchiolitis in infants
- New RSV vaccine shows promise for seniors in large trial